Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ai Takeda-Watanabe"'
Autor:
Munehiro Kitada, Ai Takeda-Watanabe, Atsushi Nakagawa, Keizo Kanasaki, Shin-ichi Tsuda, Daisuke Koya, Makoto Nishizawa, Kazunori Konishi, Mizue Fujii
Publikováno v:
BMJ Open Diabetes Research & Care
Objective The objective of this study is to elucidate the effect of anagliptin on glucose/lipid metabolism and renoprotection in patients with type 2 diabetic nephropathy. Methods Twenty-five patients with type 2 diabetic nephropathy received anaglip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff0afb4910790540e9efac2bbb0255f
http://europepmc.org/articles/PMC5530236
http://europepmc.org/articles/PMC5530236
Autor:
Toshiki Otoda, Makoto Nishizawa, Atsushi Nakagawa, Kazunori Konishi, Munehiro Kitada, Shin-ichi Tsuda, Daisuke Koya, Keizo Kanasaki, Megumi Kanasaki, Takako Nagai, Ai Takeda-Watanabe
Publikováno v:
Internal Medicine
An impaired ability to sense and respond to drug-induced hypoglycemia is a common and serious complication in diabetic patients. The hypothalamic-pituitary-adrenal (HPA) axis activity plays a critical role in the counterregulatory response to hypogly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eca87587495fbaeaf47cc1632d5920b3
https://pubmed.ncbi.nlm.nih.gov/27904111
https://pubmed.ncbi.nlm.nih.gov/27904111
Publikováno v:
Clinical Science (London, England : 1979)
Sirtuins are members of the Sir2 (silent information regulator 2) family, a group of class III deacetylases. Mammals have seven different sirtuins, SIRT1–SIRT7. Among them, SIRT1, SIRT3 and SIRT6 are induced by calorie restriction conditions and ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4055ae0b65db646f19c8a4a1d9c7496
https://doi.org/10.1042/cs20120190
https://doi.org/10.1042/cs20120190
Autor:
Ai Takeda-Watanabe, Tomoe Nomura, Atsushi Nakagawa, Yasuto Tomita, Ranji Hayashi, Yasuharu Nakano, Munehiro Kitada, Hisakazu Shiroeda, Shin-ichi Tsuda, Takako Nagai, Takeo Kosaka, Keizo Kanasaki, Nobuhiko Ueda, Megumi Kanasaki, Daisuke Koya, Makoto Nishizawa, Kazunori Konishi, Hiroki Ito, Mizue Fujii
Publikováno v:
Journal of Diabetes Investigation
Dipeptidyl peptidase (DPP)‐4 inhibitors are a new class of antidiabetic drugs that increase incretin hormone levels to enhance blood sugar level‐dependent insulinotropic effects, suppress glucagon action, and reduce bowel motility. These incretin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0e73dcbcf3a1384beb196eb3983cc1
https://doi.org/10.1111/jdi.12095
https://doi.org/10.1111/jdi.12095
Autor:
Munehiro Kitada, Keizo Kanasaki, Shin-ichi Tsuda, Ai Takeda-Watanabe, Shinji Kume, Daisuke Koya
Publikováno v:
Biochimica et biophysica acta. 1830(10)
Background Calorie restriction (CR) is accepted as an experimental anti-aging paradigm. Several important signal transduction pathways including AMPK and SIRT1 are implicated in the regulation of physiological processes of CR. However, the mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07c0d3655facc17cb2d1f5b89dad360a
https://pubmed.ncbi.nlm.nih.gov/23800577
https://pubmed.ncbi.nlm.nih.gov/23800577
Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients.
Autor:
Kanasaki, Keizo1, Konishi, Kazunori1, Hayashi, Ranji2, Shiroeda, Hisakazu2, Nomura, Tomoe2, Nakagawa, Atsushi1, Nagai, Takako1, Takeda‐Watanabe, Ai1, Ito, Hiroki1, Tsuda, Shin‐ichi1, Kitada, Munehiro1, Fujii, Mizue1, Kanasaki, Megumi1, Nishizawa, Makoto1, Nakano, Yasuharu3, Tomita, Yasuto3, Ueda, Nobuhiko3, Kosaka, Takeo3, Koya, Daisuke1
Publikováno v:
Journal of Diabetes Investigation. Nov2013, Vol. 4 Issue 6, p673-675. 3p.
Publikováno v:
Clinical Science; 2013, Vol. 124 Issue 3, p153-164, 12p